Chapter 51. Obesity. Will Obs

 Obesity

BS. Nguyễn Hồng Anh

Extensive weight gain is a major health problem today in many

auent societies. Te Centers or Disease Control and Prevention (CDC) (2020) reported the prevalence in the United

States during 2017 to 2018 to be 42 percent among all adults.

Te adverse health aspects o obesity are staggering and include

increased risks or type 2 diabetes, heart disease, hypertension,

and osteoarthritis. Importantly, obese women and their etuses

are predisposed to numerous pregnancy-related complications

and to long-term morbidity and mortality.

GENERAL CONSIDERATIONS

■ Definitions and Prevalence

O systems to classiy obesity, the body mass index (BMI), also

known as the Quetelet index, is most oten used. Te BMI is

calculated as weight in kilograms divided by the square o the

height in meters (kg/m2). Calculated BMI values are available

in various chart and graphic orms (Fig. 51-1). Te National

Institutes o Health (2000) classies adults according to BMI

as ollows: normal is 18.5 to 24.9 kg/m2, overweight is 25 to

29.9 kg/m2, and obese is ≥30 kg/m2. Obesity is urther divided

into: class 1 is 30 to 34.9 kg/m2, class 2 is 35 to 39.9 kg/m2,

and class 3 is ≥40 kg/m2. Class 3 obesity is oten reerred to

as morbid obesity, and supermorbid obesity describes a BMI

≥50 kg/m2.

Using these denitions, rom 2015 to 2016 in the United

States, among girls and women, the prevalence o obesity rose

with age and varied among ethnicities (Fig. 51-2) (Centers or

Disease Control and Prevention, 2020). Overall, severity also

advances with increasing poverty. Last, a genetic predisposition

has been identied (Locke, 2015; Shungin, 2015).

■ Adipose Patopysiology

Fat tissue is much more complex than merely its energy storage unction. Many at tissue cells communicate with all other

tissues via endocrine and paracrine actors, which are cytokines

specically termed adipokines, lipokines, and exosomal microRNAs

(Scheja, 2019). Some o these with metabolic unctions include

adiponectin, leptin, tumor necrosis actor α (NF-α), interleukin 6 (IL-6), resistin, visatin, apelin, vascular endothelial

growth actor (VEGF), lipoprotein lipase, and insulin-like

growth actor. Adiponectin is a principal adipokine. It enhances

insulin sensitivity, blocks hepatic glucose release, and has cardioprotective eects on circulating plasma lipids. An adiponectin decit is linked with diabetes, hypertension, endothelial cell

activation, and cardiovascular disease.

Cytokines that result in insulin resistance are leptin, resistin,

NF-α, and IL-6, and higher levels o these are ound during pregnancy. Indeed, adipokines, especially the inammatory

cytokines, may be the primary stimulant o insulin resistance

(Yang, 2016). Conversely, adiponectin has antiinammatory

and insulin-sensitizing roles and is negatively regulated by at

mass. Perivascular adipose tissue also serves as a signaling mediator in regulating vascular unction (Ahmadieh, 2020). Placental production o these adipokines is also important (Sartori,

2016) (Chap. 5, p. 99)


FIGURE 51-1 Chart for estimating body mass index (BMI). To find the BMI category for a particular subject, locate the point at which the

height and weight intersect.

■ Metabolic Syndrome

Given its multiaceted endocrine and paracrine unctions, the

detrimental eects o excessive adipose tissue are not surprising

(Gilmore, 2015). Obesity interacts with inherited actors to cause

insulin resistance. Tis resistance is characterized by impaired glucose metabolism and a predisposition to type 2 diabetes. Insulin

resistance also causes several subclinical abnormalities that predispose to cardiovascular disease and accelerate its onset. Te most

important among these are type 2 diabetes, dyslipidemia, and

hypertension, which are constituents o the metabolic syndrome.

Criteria to dene this syndrome are ound in Table 51-1.

Waist circumerence is the preerred measurement or screening, but any three o ve actors listed are sufcient to diagnose

the metabolic syndrome. Notably, most patients with type 2

diabetes have metabolic syndrome according to these criteria.

Also, obese women with hypertension typically demonstrate

elevated plasma insulin levels.

FIGURE 51-2 Prevalence of obesity in the United States by race:

United States 2015–2016.


TABLE 51-1. Criteria for Diagnosis of the Metabolic
Syndrome


Te National Health and Nutrition Examination Survey

(NHANES) o the CDC documented an overall prevalence o

34 percent or the metabolic syndrome in the United States

by 2012 (Moore, 2017). As expected, the prevalence rose with

age. It was 20 percent or those aged 18 to 29 years and was

36 percent or those aged 30 to 49 years.

■ Nonalcoolic Fatty Liver Disease

Generally speaking, visceral adiposity correlates with hepatic

at content (Cornier, 2011). With obesity, excessive at accumulates in the liver and is termed hepatic steatosis. Tis is also

called nonalcoholic fatty liver disease (NAFLD). In persons with

the metabolic syndrome, steatosis can progress to nonalcoholic

steatohepatitis (NASH) and then potentially to cirrhosis and

hepatocellular carcinoma. It is the major cause o cirrhosis and

liver cancer, and annual medical costs o NAFLD in the United

States exceed $100 billion (Diehl, 2017). Moreover, NAFLD is

strongly associated with cardiovascular disease (argher, 2016).

Tese interactions are explored urther in Chapter 58 (p. 1040).

■ Obesityassociated Morbidity

Obese individuals suer well-known consequences such as glucose intolerance, hypertension, dyslipidemia, and metabolic

syndrome. Furthermore, metabolic syndrome and obesity are

linked with cardiovascular disease, including myocardial inarction, atrial brillation, heart ailure, and stroke (Koliaki, 2019).

Excessive adiposity raises blood pressure and accounts or up

to 75 percent o primary hypertension (Hall, 2019). Insulin

resistance and metabolic syndrome cause structural cerebral

changes in the hippocampus and lower executive unctioning

and memory in adults (Kullman, 2016). And cytokine-induced

osteoarthritis has long been linked to obesity (u, 2019).

Because o the oregoing, it is not surprising that obesity is

associated with higher rates o all-cause early mortality. Cardiovascular mortality data rom 19 prospective studies are

shown in Figure 51-3 (Gonzalez, 2010). In these and other

studies, mortality risk rom cardiovascular disease and cancer

grew proportionally with increasing BMI. However, an obesity paradox—whereby certain groups actually derive a survival

advantage rom being obese—is hypothesized (Hainer, 2013).

Despite this, the health benets o weight normalization are

well documented (Cheung, 2017).

■ Obesity Treatment

Weight loss is tremendously difcult. I achieved, long-term

maintenance poses equally daunting challenges. Obstetriciangynecologists are encouraged to aid weight loss in obese adult

women. Successul approaches include behavioral, pharmacological, and surgical techniques or a combination o these (Dixon,

2016; Heymseld, 2017). Dietary changes and exercise reduce

weight and rates o the associated metabolic syndrome (Garvey,

2016; Martin, 2018). When used in conjunction with bariatric

surgery, glucose control in those with type 2 diabetes is improved.

However, both surgical and medical interventions are associated

with appreciable long-term ailure rates. Indeed, the ailure rate is

50 percent in patients with diabetes undergoing bariatric surgery

(Mingrone, 2015).

FIGURE 51-3 Estimated hazard ratios (95% CI) for death due

to cardiovascular disease according to body mass index among

1.46 million white adult men and women.

PREGNANCY AND OBESITY

Obese women unequivocally have reproductive disadvantages (Lainez, 2019). Tis translates into difculty in achieving pregnancy, early and recurrent pregnancy loss, preterm

delivery, and several obstetrical, medical, and surgical complications with pregnancy, labor, delivery, and the puerperium

(American College o Obstetricians and Gynecologists, 2021).

Also, oral contraceptive pill ailure and associated thromboembolism may be more likely. Second-trimester surgical abortion

in obese women also carries an increased complication risk

(Mark, 2018). Last, inants—and later, adult children—o

obese mothers have correspondingly higher morbidity rates

(Godrey, 2017; He, 2020).

Obesity complicating pregnancy has grown substantially in

this country. Our experiences at Parkland Hospital over three

epochs are shown in Figure 51-4. Most recently, obese women

constitute >60 percent o pregnant gravidas in our health system.

FIGURE 51-4 Increasing prevalence of obesity during four epochs

in pregnant women classified at the time of their first prenatal visit

at Parkland Hospital.


TABLE 51-2. Adverse Pregnancy Effects in Overweight and Obese Women

Maternal Morbidity

For overweight women, higher rates o adverse outcomes complicate pregnancy. Shown in Table 51-2 are results rom ve

studies including more than 1 million singleton pregnancies.

Although not as magnied as in the obese cohort, rates o

almost all complications are signicantly greater in overweight

women than in those with normal BMI.

For obese women, denitions used in studies o adverse outcomes vary widely, and BMIs rom >30 kg/m2 to >50 kg/m2

have served as thresholds (Crane, 2013; Pratt, 2020; Stamilio, 2014). In one study, Mariona (2017) reviewed maternal

deaths in Michigan and ound that the maternal mortality

rate was nearly ourold higher in obese women. Women with

supermorbid obesity experience very high rates o maternal and

neonatal complications including preeclampsia, macrosomia,

and cesarean delivery, along with higher rates o neonatal

meconium aspiration, ventilator support, and neonatal death

(Marshall, 2014; Smid, 2016). Data rom one large study are

shown in Figure 51-5 (Weiss, 2004).

Especially striking are the markedly elevated rates o hypertension and gestational diabetes. As discussed previously, obesity and the metabolic syndrome are characterized by insulin

resistance, which creates low-grade inammation, endothelial

activation, and increased sodium reabsorption (Hall, 2019).

Tese latter eects play a central role in preeclampsia (Chap.

40, p. 691). Te overwhelming association between rising

maternal BMI and the incidence o preeclampsia is depicted

in Figure 51-6 (HAPO Study Cooperative Research Group,

FIGURE 51-5 Incidence of selected pregnancy outcomes in women enrolled in the FASTER (First-and Second-Trimester Evaluation of Risk)

trial according to BMI.


FIGURE 51-6 Hyperglycemia and Adverse Pregnancy Outcome

(HAPO) study: frequency of preeclampsia according to BMI

2008). Te risks or hypertension are highest in women with

a BMI >50 kg/m2 (Pratt, 2020). Similar observations were

reported rom a large Canadian study and by the Sae Labor

Consortium (Kim, 2016; Schummers, 2015).

Obesity and hypertension are common coactors in peripartum heart ailure (Cunningham, 2012). Stewart and colleagues

(2016) used magnetic resonance imaging to prospectively

study the eect o obesity on cardiac remodeling in pregnancy.

Concentric remodeling, which was considered abnormal, was

greater in overweight or obese women (Fig. 51-7). Tis, however, regressed to normal by 3 months postpartum. riebwasser

and coworkers (2019) ound that women with abnormal cardiac remodeling had a higher incidence o pregnancy-associated

hypertensive disorders.

Obesity and gestational diabetes are inextricably linked as

shown in able 51-2. Teir coexistence and associated adverse

pregnancy outcomes are discussed in Chapter 60 (p. 1068).

Nonalcoholic atty liver disease is associated with several adverse

pregnancy outcomes (Chap. 58, p. 1040). In a cohort o women

30

20

10

2.1 2.9

4.8

8.2

12.1

23.4

30.4

0

≤23.2

23.3–26.7

26.8–30.5

30.6–33.6

33.7–38.3

38.4–44

>44

Body mass index (kg/m2)

Incidence (percent)

FIGURE 51-6 Hyperglycemia and Adverse Pregnancy Outcome

(HAPO) study: frequency of preeclampsia according to BMI.

12–16

LVM / LVEDV (g/mL)

26–30

Pregnancy (weeks)

32–36 3 mos

Postpartum

0.60

0.65

0.70

0.75

0.80

0.85

Obese

Normal-weight

FIGURE 51-7 Geometric changes of ventricular remodeling

across pregnancy in obese and normal-weight women determined

by cardiac MR imaging. LVM = left ventricular mass,

LVEDV = left ventricular end-diastolic volume.

with NAFLD, risks or preeclampsia, preterm birth, low-birthweight neonates, cesarean delivery, and gestational diabetes were

elevated (Hagström, 2016). In one prospective study o 476

pregnancies, rst-trimester sonographic evidence o maternal

NAFLD was strongly associated with gestational diabetes (De

Souza, 2016a,b). Meyer and associates (2013) ound that overweight and obese gravidas had a higher proportion o low-density

lipoprotein III (LDL-III) compared with that o normal-weight

women. LDL-III predominance is a hallmark o the ectopic liver

at accumulation that is typical o NAFLD. At Parkland Hospital, we are now requently encountering obese gravidas who have

NAFLD and evidence o steatohepatitis maniest by elevated

serum hepatic transaminase levels. In rare cases, liver biopsy is

necessary to exclude other causes or these ndings.

Quality-o-lie measures also are negatively aected by

obesity during pregnancy (Ruhstaller, 2017). One systematic

review ound signicantly higher risks o depression in overweight and obese women during and ater pregnancy (Molyneaux, 2014). Obese women were also signicantly more likely

to experience anxiety during pregnancy.

■ Perinatal Mortality

Stillbirths are more prevalent as the degree o obesity accrues

(Schummers, 2015). In a review o almost 100 studies, obesity was the highest-ranking modiable risk actor or stillbirth

(Flenady, 2011). In women with supermorbid obesity compared

with normal-weight gravidas, Yao and associates (2014) ound 5.7

and 13.6-old higher stillbirth rates at 39 and 41 weeks’ gestation,

respectively. Remarkably, 25 percent o term stillbirths in this

study involved obese women. Chronic hypertension with superimposed preeclampsia associated with obesity is one cause o excessive stillbirths. Tese etal deaths may be associated with placental

lesions o decidual arteriopathy and inarctions (Avagliano, 2020).

Evaluating perinatal death rates, Lindam and coworkers

(2016) reported that high maternal BMI in early pregnancy was

a risk actor. Te risk o neonatal death also is greater or obese

women (Johansson, 2014; Meehan, 2014). Last, one study

ound that accruing weight between pregnancies is a risk actor

or perinatal mortality, whereas weight loss between pregnancies or overweight women lowers this risk (Cnattingius, 2016).

■ Perinatal Morbidity

Both etal and neonatal complication rates are increased in obese

women. wo important and interrelated coactors that contribute to excessive rates o perinatal morbidity are chronic hypertension and diabetes, both o which are associated with maternal

obesity. Tese comorbidities each may play a role in the higher

rates o etal-growth restriction and indicated preterm birth that

are seen in obese women (Liu, 2019; anner, 2020). Perinates

o obese women with preterm prematurely ruptured membranes

have a higher incidence o respiratory complications than those

born to normal-weight women (Lynch, 2020). Pregestational

diabetes also raises the birth deect rate, and gestational diabetes

is complicated by excessive numbers o large-or-gestational-age

and macrosomic etuses (Chap. 47, p. 833).

Even when diabetes and hypertension are not considered,

the prevalence o neonatal morbidity is greater in ospring

o obese women (Kim, 2016; Polnaszek, 2018; Schummers,

2015). Te propensity or preterm birth may be related to

increased adipokines and cytokines causing chronic inammation (ersigni, 2020). Te group rom MetroHealth

Medical Center in Cleveland has extensively studied prepregnancy obesity, gestational weight gain, and diabetes

and their relationship to adverse pregnancy outcomes and

to greater newborn weight and at mass (Catalano, 2015;

Ma, 2016; Yang, 2016). Although each o these variables is

associated with larger and more corpulent newborns, prepregnancy BMI and its eect on inammation and placental

gene expression has the strongest inuence on the prevalence

o macrosomic neonates.

Rates o birth deects also are higher with obesity (Auger,

2019). For neural-tube deects, elevated risks o 1.2-, 1.7-,

and 3.1-old have been described or overweight, obese, and

severely obese women, respectively (Rasmussen, 2008). Te

National Birth Deect Prevention Study reported a correlation between BMI and congenital heart deects (Gilboa, 2010).

However, this may be related to diabetes as a coactor (Biggio,

2010). Importantly, obesity degrades the accuracy o obstetrical

ultrasound examination and antepartum identication o birth

deects (Adekola, 2015; Dashe, 2009; Yaqub, 2021).

■ Longterm Offspring Morbidity

Obese women beget obese children, who themselves become

obese adults. Catalano and coworkers (2009) studied ospring

at a mean age o 9 years and ound a direct association with

maternal prepregnancy obesity and childhood obesity. Tey

also reported associations with central obesity, elevated systolic

blood pressure, increased insulin resistance, and lipid abnormalities—all elements o the metabolic syndrome. Reynolds

and associates (2013) reported higher rates o cardiovascular

disease and all-cause mortality in 37,709 adult ospring o

overweight and obese mothers. Similar cardiometabolic health

eects in ospring were echoed by Gaillard and colleagues

(2016). Other data suggest that excessive maternal weight gain

in pregnancy may predict obesity in adult ospring (Lawrence,

2014). Last, rates o glucose intolerance and metabolic syndrome are higher among ospring o obese women (Gaillard,

2016).

Te potential biological mechanisms o these associations

are unclear. But such studies raise the possibility o fetal programming, that is, the etal environment may lead to adverse

adult health outcomes. Elucidation is limited by insufcient

data regarding the inuence o maternal and genetic predisposition compared with the diet and activity environment o the

inant and child (Gluck, 2009). Te science o epigenetics has

provided some support or the possibility that perturbations o

the maternal–etal environment can adversely alter postdelivery

events (Kitsiou-zeli, 2017).

ANTEPARTUM MANAGEMENT

■ Maternal Weigt Gain

Te Institute o Medicine (2009) has updated its previous

maternal weight gain determinants (able 10-4, p. 183). For

overweight women, weight gain o 15 to 25 pounds is suggested. For obese women, the Institute recommends a gain o

11 to 20 pounds. Intuitively, maternal weight must increase

sufciently to provide or etal and placental tissue accrual

and or amnionic uid and maternal blood volume expansion.

Tus, maternal weight loss during pregnancy is discouraged.

Te American College o Obstetricians and Gynecologists

(2021) endorses these guidelines.

It is emphasized that these recommendations were issued

without rm scientic evidence to support them, and their

value remains unproven (Comstock, 2019; Most, 2019). For

example, recent studies dier with respect to the eect o insu-

cient weight gain or obese women. Bodnar and colleagues

(2016) reported no greater risk or low-birthweight or small-

or-gestational-age newborns among 47,494 obese women who

had inadequate weight gain during pregnancy. Bogaerts and

associates (2015) also ound that even weight loss among obese

women did not yield poor etal growth. In contrast, however,

Hannaord and coworkers (2017) reported that obese women

who gained less than the Institute recommendations were

almost three times more likely to deliver a small-or-gestationalage neonate. Another study similarly ound an almost twoold

greater risk o growth-restricted newborns among obese women

who lost weight during pregnancy (Cox Bauer, 2016).

Excessive gestational weight gain may portend greater risks

or the obese mother. Berggren and coworkers (2016) noted that

overweight and obese women accrued maternal at with excessive

gestational weight gain. From another analysis, overall higher

rates o hypertensive disorders, cesarean delivery, and etal overgrowth and lower rates o spontaneous preterm birth and etal

undergrowth were ound among women gaining more than recommended (Johnson, 2013). However, when analyzed according to BMI category, signicantly higher rates o preeclampsia,

cesarean delivery, and etal overgrowth were identied among

the 1937 overweight women, but not the 1445 obese women,

who gained excess weight. Last, overweight and obese women

have excessive postpartum weight retention (Siegel, 2020).

■ Dietary Intervention

Several dietary interventions can help limit and achieve the

weight gain targets listed in the previous section. Options

include liestyle changes such as changes in physical activity. In

one randomized trial o exercise in 300 overweight women, risks

or gestational diabetes were lowered (Wang, 2017). In other

trials, however, dietary intervention had no eect on weight gain

(Okasene-Gaa, 2019; Seneviratne, 2016). Also, a Cochrane

database analysis o 11,444 women suggests that liestyle interventions coner only a modest reduction in maternal weight

gain, and their benets or etal overgrowth, cesarean delivery

rate, and adverse neonatal outcome are not signicant (Muktabhant, 2015). Last, metormin treatment or obese pregnant

women does not improve pregnancy outcomes (Dodd, 2018).

Regarding neonatal outcomes, the poor success o liestyle

interventions during pregnancy has been attributed to their

late introduction. In this regard, it is presumed that early gene

expression within the placenta has already been programmed

(Catalano, 2015).

■ Prenatal Care

Close prenatal monitoring detects most early signs o diabetes or

hypertension. Early gestational diabetes screening did not result

in less morbidity compared with standard screening (Harper,

2020). Obstructive sleep apnea is common in obese women

(Dominquez, 2018). Standard screening tests or etal anomalies

are sufcient, while remembering the sonographic limitations

or etal anomaly detection in this group. Even so, ultrasound

predicts etal weight accurately in these women (O’Brien,

2020). Accurate etal-growth surveillance in obese women usually requires serial sonographic assessment. Dude and coworkers

(2019) reported that ultrasound as a detection tool had high

specicity but poor sensitivity or growth restriction and a low

positive predictive value or macrosomia. Antepartum external

etal heart rate monitoring is likewise more difcult.

INTRAPARTUM MANAGEMENT

Obesity poses increased risk or multiple labor or intrapartum

complications. Tese include postterm pregnancy or labor

abnormalities (Carpenter, 2016; Shenouda, 2020). In one

study o 143,519 women, the odds o spontaneous labor at

term in obese women was approximately hal that o normalweight women (Denison, 2008). In an analysis o more than

5000 parturients, women with a BMI >30 kg/m2 had a longer

duration and slower early progression o rst-stage labor (Norman, 2012). Epidural analgesia apparently does not aect the

length o labor in obese women (Polónia Valente, 2020).

■ Labor Induction

As shown in able 51-2, compared with normal-weight women,

obese women are nearly twice as likely to undergo labor induction

(Denison, 2008). However, obese women are more likely to experience a ailed induction, and this risk rises with increasing obesity

(Kerbage, 2020). Te duration o labor resulting in vaginal delivery lengthens with increasing maternal BMI (Carlhäll, 2020). In a

retrospective analysis o 470 nulliparous women with a BMI >30

kg/m2, those who underwent labor induction at 39 weeks’ gestation had a greater cesarean delivery rate—26 versus 40 percent

compared with a cohort expectantly managed (Wole, 2014). In

a study o 485 women with class III obesity, the overall cesarean

delivery rate ater ailed induction was 49 percent (Paidas eeey,

2020). Te rate was 46 percent or those with a BMI 30–40, 63

percent or a BMI 40–50, and 69 percent or a BMI >60.

Although perhaps not unexpected, these ndings have been

challenged. Lee and associates (2016) reviewed statistics rom

74,725 deliveries in obese women and reported that elective

induction at 37 to 39 weeks’ gestation was actually associated

with a lower cesarean delivery rate. Additionally, in a secondary analysis o one randomized trial, obese nulliparas who were

randomly assigned to Foley catheter cervical ripening plus

misoprostol or labor induction had a reduced labor duration

and lower rate o cesarean delivery compared with those given

solely misoprostol (Seasely, 2021). Tese conicting results

highlight the difculties aced by obstetricians as they contemplate the seemingly competing interests o the etus and the

obese mother.

■ Anestesia Risks

Obese women present anesthesia challenges that include difcult epidural and spinal analgesia placement and complications

rom ailed or difcult intubations. Evaluation o gravidas with

supermorbid obesity by the anesthesiologist is recommended

during prenatal care or upon arrival to the labor unit (American

College o Obstetricians and Gynecologists, 2019b).

Regional analgesia or morbidly obese women is associated

with longer neuraxial procedure times and more ailed placement attempts (Li, 2019). Importantly, however, spinal analgesia

in obese women or cesarean delivery does not appear to have

greater benets than combined spinal-epidural. One study comparing single-shot spinal analgesia and combined spinal-epidural

analgesia ound that both methods could be placed with equal

expediency and efcacy in morbidly obese gravidas (Ross, 2014).

Obese women who undergo neuraxial analgesia that is

complicated by relative hypotension more requently have

neonates with umbilical artery cord blood acidemia, which

probably stems rom delayed delivery. One study o 572

obese women showed that cord blood pH signicantly

dropped and base decit rose with increasing BMI (Edwards,

2013). Te rate o gases with a pH <7.1 doubled rom

3.5 percent or a BMI <25 kg/m2 to 7.1 percent or a BMI

≥40 kg/m2. Anesthetic risks and complications are discussed

in Chapter 25.

■ Cesarean Delivery

As shown in able 51-2, rates o cesarean delivery are signicantly

greater in obese women compared with normal-weight gravidas.

In an analysis o 226,958 women, cesarean delivery rates rose

signicantly or overweight (34 percent), class I (38 percent),

class II (43 percent), and class III (50 percent) obesity (Schummers, 2015). Our experiences at Parkland Hospital are similar

(Fig. 51-8). Moreover, obese women had less composite morbidity when labor was attempted compared with cesarean delivery

(Gibbs Pickens, 2018; Grasch, 2017). More worrisome is that

obese women also have higher rates o emergency cesarean delivery,

and obesity lengthens times or decision-to-incision and or delivery (Girsen, 2014; Pulman, 2015).

1990–1991

Cesarean delivery (percent)

40

Normal

Overweight

Obese

30

20

10

0

1992–2001 2002–2012 2013–2019

FIGURE 51-8 Cesarean delivery rates in more than 300,000

women according to BMI categories over a 30-year period at Parkland Hospital.

Discussed in Chapter 31 (p. 577), the incidence o ailed trial

o labor ater cesarean is higher in obese women (Grasch, 2017;

Wilson, 2020). Women who gain weight between pregnancies

also have signicantly lower rates o vaginal birth ater cesarean.

■ Surgical Concerns

For cesarean delivery, orethought is given to optimal placement

and type o abdominal incision to provide access to the etus and

to eect the best wound closure. We preer a vertical incision in

obese women to provide the most direct access (Fig. 51-9). Others preer a low transverse abdominal incision, with or without

rostral taping o the pendulous abdomen (Karimyar, 2020; Lakhi,

2018). Individual dierences in maternal body habitus preclude

naming any one approach as superior (uran, 2016). Some observational studies have compared wound outcomes associated with

A B

FIGURE 51-9 Abdominal incision for the obese woman. A. Frontal view. The dotted line indicates an appropriate skin incision for

abdominal entry relative to the panniculus. As shown by the uterus

in the background, selection of this periumbilical site permits

access to the lower uterine segment. B. Sagittal view.

vertical and transverse skin incisions, but results are conicting as

to a superior option (Karimyar, 2020; Marrs, 2014; Sutton, 2016).

Te requency o abdominal wound inections is directly

related to BMI. Conner and associates (2014) ound the

risk o wound inection is threeold higher—23 versus 7

percent—in women with supermorbid obesity compared

with nonobese patients. Among women with a BMI >45

kg/m2, reported wound complication rates range rom 14

to 19 percent (Smid, 2015; Stamilio, 2014). Comorbid diabetes apparently raises this risk (Leth, 2011). Other studies

describe wound complication rates ranging rom 2 to >40

percent in obese women (Conner, 2014; Marrs, 2014; Smid,

2015; Tornburg, 2012).

Several interventions may be preventive. Closure o subcutaneous tissue when at least 2 cm deep reduces wound complication rates (ipton, 2011). Steel staples and subcuticular skin

closure produce identical results (Zaki, 2018). Studies have also

examined the use o higher doses o perioperative prophylactic

antibiotics. Pharmacokinetic studies indicate that tissue concentrations o prophylactic antibiotics are lower with increasing BMI (Pevzner, 2011; Young, 2015). One prospective study

showed that a 3-g dose o ceazolin resulted in higher tissue

concentrations compared with a 2-g dose (Swank, 2015). A retrospective analysis o 335 women with a median weight o 310

pounds ound that the higher dose o ceazolin did not result

in ewer surgical site inections (SSIs) (Ahmadzia, 2015). Te

American College o Obstetricians and Gynecologists (2020)

recognizes either 2- or 3-g doses o ceazolin as suitable or

those with weights ≥80 kg. Te Centers or Disease Control

and Prevention recommends a 2-g dose or weights ≥80 kg

and 3-g dose or those ≥120 kg (Berríos-orres, 2017). One

pharmacokinetic analysis in obese women showed sufcient

tissue levels with a 2-g dose or cesarean deliveries lasting 1.5

hours. Authors recommended consideration or redosing in

obese women i surgeries were longer (Grupper, 2016). Last,

some early evidence may support extending oral antibiotic prophylaxis or 48 hours postcesarean in obese women to lower

SSIs (Valent, 2017). Obese women administered preoperative

cephalosporin prophylaxis had a surgical inection rate o 13.4

percent compared with a rate o 6.4 percent or those given a

2-day postoperative course o oral cephalexin and metronidazole

in addition to routine preoperative prophylaxis.

Negative-pressure wound therapy (NPW) also has been

used prophylactically (Mark, 2014). o address this, Hussamy

and colleagues (2019) designed a randomized trial o NPW

versus routine dressing in 441 obese women undergoing cesarean delivery. Such therapy did not signicantly lower the postoperative wound complication rate compared with routine

care—17 versus 19 percent, respectively. A subsequent report

conrmed these ndings (uuli, 2020).

For the obese woman who is delivered vaginally, puerperal

tubal sterilization is sae regardless o BMI (Byrne, 2020). Tese

procedures are described in Chapter 39. Te risks or postpartum venous thromboembolism are increased in obese women.

Tis is despite the act that velocity o lower-extremity blood

ow is increased in obese pregnant women (Dutta, 2020). As

discussed in Chapter 55 (p. 990), thromboprophylaxis is controversial. o lower thromboembolic complications, graduated

compression stockings, hydration, and early mobilization ater

cesarean delivery in obese women are recommended by the

American College o Obstetricians and Gynecologists (2019b).

I there are additional risk actors other than class III obesity, the

Society or Maternal-Fetal Medicine (2020) recommends enoxaparin. We do not routinely use thromboprophylaxis or obesity

alone at Parkland Hospital. Tis practice has recently been con-

rmed by Lu and associates (2021).

BARIATRIC SURGERY

Several surgical procedures are designed to treat morbid obesity

either by diminishing gastric volume (restrictive) or by bypassing gastrointestinal absorption (restrictive malabsorptive). In

nonpregnant patients, these procedures serve to improve or

resolve diabetes, hyperlipidemia, hypertension, and obstructive

sleep apnea and to reduce risks o myocardial inarction and

death (Beamish, 2016).

■ Restrictive Procedures

O options, the approved laparoscopic adjustable silicone gastric banding (LASGB) procedure—LAPBAND—places a band

2 cm below the gastroesophageal junction to create a small

stomach pouch above the ring. Te ring diameter is controlled

by a saline reservoir in the band.

Tese procedures can have positive eects on pregnancy outcomes. One study compared pregnancy outcomes in bariatric

surgery patients whose surgery was done ater the rst pregnancy. Following bariatric surgery, the incidences o hypertension, gestational diabetes, and preterm birth were signicantly

lower in the bariatric surgery patients (Ibiebele, 2020). Te

results rom these and other studies are shown in Table 51-3.

Deation o the band during pregnancy aects maternal

and etal weight gain. Pilone and coworkers (2014) studied 22

pregnancies ater band placement and reported that all women

underwent ull deation o the band in the rst trimester and

gained an average o 14.7 kg during pregnancy. In another

study, 42 women underwent deation o the band, whereas

54 women maintained band ination. A deated band was

associated with higher mean maternal weight gain—15.4 kg

versus 7.6 kg, increased birthweight—3712 versus 3380 g, and

a twoold greater risk o macrosomia compared with an inated

band (Cornthwaite, 2015). Rarely, the band may slip due to

nausea and vomiting, especially with advancing gestation or

ater delivery (Pilone, 2014; Schmitt, 2016; Suee, 2012). One

etus suered a atal cerebral hemorrhage caused by maternal

vitamin K deciency secondary to prolonged vomiting due to

band slippage that created a gastric outlet obstruction (Van

Mieghem, 2008).

■ Restrictive Malabsorptive Procedures

Te laparoscopically perormed Roux-en-Y gastric bypass is the

most commonly used procedure or gastric restriction and selective malabsorption. Pregnancy outcomes are changed remarkably ollowing Roux-en-Y bypass (Adams, 2015). As shown in

able 51-3, rates o hypertension, gestational diabetes, and etal

macrosomia are reduced.

Serious complications with bypass operations are uncommon, however, upper abdominal pain is requent in pregnancy

and may be associated with internal herniation, which is protrusion o the bowel through a window deect in the mesentery. Petersen and associates (2017) described outcomes in

a birth cohort including 139 pregnancies. Upper abdominal

pain complicated 46 percent, and a third o these had internal

herniation. Te preterm birth rate was 14 o 64 among those

with upper abdominal pain versus 1 o 75 in those without

pain. Intussusception and small bowel obstruction can develop

rom internal herniation, and maternal deaths rom herniation

and obstruction are reported (Moore, 2004; Renault, 2012).

Bowel obstruction is notoriously difcult to diagnose during

pregnancy (Vannevel, 2016; Wax, 2013).

■ Pregnancy

Because o its associated health successes, bariatric surgery is

popular, and many women subsequently become pregnant

(Narayanan, 2016). From studies, ertility improves and

obstetrical complication rates decline in women ater bariatric surgery compared with morbidly obese controls (Getahun,

2021; Kominiarek, 2017; Yi, 2015). In one o these studies,

despite surgical treatment, almost hal o 670 women were

still obese at the time o their rst pregnancy ater bypass

(Johansson, 2015). Nevertheless, the requency o large-orgestational-age newborns dropped rom 22 to 8.6 percent and

o small-or-gestational-age neonates rose rom 7.6 to 15.6

percent. In a systematic review, Kwong and colleagues (2018)

conrmed these etal weight trends ater bariatric surgery.

According to Maric and colleagues (2020), etuses are smaller

because o lower maternal glucose levels rather than alterations o the etoplacental circulation. Also, risks or diabetes

and preeclampsia were reduced. Last, evidence suggests that

the risk or congenital anomalies is decreased (Auger, 2019;

Neovius, 2019).

Currently, the American College o Obstetricians and Gynecologists (2019b) recommends that women who have undergone bariatric surgery be assessed or vitamin and nutritional

sufciency. When indicated, vitamins B12 and D, olic acid,

and calcium supplementation are given. Vitamin A deciency

also is possible (Chagas, 2013). Women with a gastric band

should be monitored by their bariatric team during pregnancy

because band adjustments may be necessary. Last, special vigilance or signs o internal herniation with intestinal obstruction

is encouraged (Stuart, 2017; Wax, 2013)



Nhận xét